Latest Tax Incentives News

Actinogen Medical accelerates recruitment in its pivotal XanaMIA Alzheimer's trial while securing a strong cash position of $22.9 million, underpinning its late-stage development and commercial readiness.

Syntara Limited has reported encouraging interim Phase 2 trial results for its lead drug candidate SNT-5505 in myelofibrosis, alongside a successful A$15 million capital raise to advance multiple clinical programs.

Aruma Resources advances its exploration portfolio with standout assay results at Fiery Creek and strategic leadership changes, setting the stage for upcoming drilling campaigns.

Syntara Limited reported a robust $11.35 million increase in cash during the December 2024 quarter, underpinned by government grants and steady operational inflows. The company closes the period with a strong cash position of $18.07 million, signaling financial resilience.

4DMedical reports a remarkable 202% increase in Q2 FY2025 operating revenue, driven by rapid site expansion and key collaborations with leading healthcare providers and the U.S. Department of Defense.

Livium Ltd reports a 179% surge in recycling gross profit and advances its lithium extraction technology, positioning itself strongly in the evolving battery materials market.

Noxopharm’s December 2024 quarterly report reveals expanding global interest in its Sofra technology through new Material Transfer Agreements and a strengthened cash position following a significant R&D tax rebate.

Mighty Kingdom Ltd has received $1.809 million in tax rebates, significantly enhancing its capital flexibility as it refines operations and explores future growth opportunities.

AnteoTech has marked a pivotal quarter with its first commercial Ultranode™ order shipped to Mercedes-Benz and a $4.3 million capital raise to accelerate growth in clean energy and life sciences.

Zeotech Limited has secured a strategic MOU with Holcim Australia to advance its AusPozz™ low-carbon concrete product, alongside promising methane reduction results and a newly granted Japanese patent.

IDT Australia reports a near doubling of quarterly revenue to $5.3 million, driven by explosive growth in its Advanced Therapies segment, with first-half revenue expected to jump 82%.

Dimerix Limited has inked a lucrative licensing agreement with Fuso Pharmaceutical for its kidney disease drug DMX-200 in Japan, while completing recruitment for its pivotal Phase 3 ACTION3 trial.